Evidence map›Paper›PMID 41176764›Full record

ArticleCell reports2025

Mpox-specific cellular and humoral immunity in mpox survivors living with HIV.

Samuel D Stampfer, Lalita Priyamvada, Shainy Sambyal, Sailaja Gangadhara, Margaret Moriarty, Panayampalli S Satheshkumar, Alba Grifoni, Alessandro Sette, Anandi N Sheth, Colleen F Kelley and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Samuel D StampferDivision of Microbiology and Immunology, Emory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, GA, USA; Department of Microbiology and Immunology, Emory School of Medicine, Emory University, Atlanta, GA, USA; Division of Infectious Diseases, Department of Medicine, Emory School of Medicine, Emory University, Atlanta, GA, USA. Electronic address: sstampf@emory.edu.
Lalita PriyamvadaPoxvirus and Rabies Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Shainy SambyalDivision of Microbiology and Immunology, Emory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, GA, USA; Department of Microbiology and Immunology, Emory School of Medicine, Emory University, Atlanta, GA, USA.
Sailaja GangadharaDivision of Microbiology and Immunology, Emory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, GA, USA; Department of Microbiology and Immunology, Emory School of Medicine, Emory University, Atlanta, GA, USA.
Margaret MoriartyPoxvirus and Rabies Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Panayampalli S SatheshkumarPoxvirus and Rabies Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Alba GrifoniCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA.
Alessandro SetteCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA, USA.
Anandi N ShethDivision of Infectious Diseases, Department of Medicine, Emory School of Medicine, Emory University, Atlanta, GA, USA; Grady Health System, Atlanta, GA, USA.
Colleen F KelleyDivision of Infectious Diseases, Department of Medicine, Emory School of Medicine, Emory University, Atlanta, GA, USA; Grady Health System, Atlanta, GA, USA.
Rama R AmaraDivision of Microbiology and Immunology, Emory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, GA, USA; Department of Microbiology and Immunology, Emory School of Medicine, Emory University, Atlanta, GA, USA. Electronic address: ramara@emory.edu.

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
Induction of Broad Sarbecovirus Immunity Via A Vaccine Engineered From SARS-CoV-2 Heptad Repeat 1K08AI180431 · NIAID · EMORY UNIVERSITY · PI Samuel David Stampfer · 2024 to 2026
$545k
NIAID NIH HHS K08 AI180431NIAID NIH HHS P30 AI050409NIH HHS P51 OD011132
6 · The paper itself

Abstract

The 2022 mpox virus (MPXV) outbreak caused life-threatening mpox disease in people living with HIV (PLWH). We compared immune responses to MPXV in PLWH who were either mpox-naive or were mpox survivors. We characterized the magnitude, polyfunctionality, and cytolytic potential of CD4 and CD8 T cells specific to MPXV and cross-reactive orthopoxviral antigens and compared them to HIV- and cytomegalovirus (CMV)-specific T cells. Mpox survivors developed MPXV-specific CD4 T cells capable of producing IFNγ, TNFα, and IL-2. Their polyfunctionality was superior to CMV-specific CD4 T cells. MPXV- and CMV-specific CD8 T cells had similar cytolytic potentials. Importantly, mpox survivors developed strong MPXV-specific antibodies with neutralizing activity. Prior vaccinia or JYNNEOS vaccination was associated with greater MPXV-specific antibody but not T cells. These data demonstrate that PLWH generate functional cellular and humoral immunity to MPXV post-mpox. Despite their immunocompromised state, mpox survivors with HIV are expected to have some protection against future MPXV exposures.

Indexed as

HIV InfectionsImmunity, CellularImmunity, HumoralMpox, MonkeypoxAdultAntibodies, ViralCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFemaleHumansMaleMiddle AgedSurvivorsAntibodies, Viralantibodycellular immunityCP: ImmunologyHIVICSintracellular cytokine stainingJYNNEOSmonkeypox virusmpoxneutralizingpolyfunctionality

Identifiers

PMID41176764
PMCPMC12880552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.